Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Deferiprone Market size was over USD 40 million in 2024 and is projected to reach USD 62.5 million by the end of 2037, growing at a CAGR of 3.8% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of deferiprone is assessed at USD 41.5 million.
Deferiprone is an iron chelator that helps in aiding patients suffering from acute thalassemia syndromes. It has been readily approved by the U.S. FDA and is commonly known as Ferriprox. As per an article published by MDPI in July 2023, deferiprone is regularly utilized by patients with a dosage ranging between 75 to 100 100 mg/kg for over 30 years with the absence of toxicity. However, through continuous clinical trials, there are side effects that affect 1% to 5% of patients, but they are reversible as well as manageable. Besides, deferiprone is widely utilized for overcoming iron loading conditions that include the orphan drug category and other clinical conditions, thereby driving the deferiprone market globally.
Moreover, the upliftment of the market hugely depends on its implementation to combat sickle cell disease. According to the February 2023 NLM article, people suffering from this disease, as well as anaemia, are highly prone to transfusional iron overload, and the suggested dose ranges from 25 to 33 mg/kg body weight. Additionally, it is to be consumed orally and three times a day to complete the dose of 75 mg/kg to 100 mg/kg body weight. The article has displayed the pricing strategy of deferiprone, including USD 33.47 for a 1,000 mg tablet and USD 3.35 per mL for 100 mg/mL oral solution. Besides, the monthly pricing ranges between USD 6,113.0 to USD 8,151.0, therefore suitable enough for the market to expand internationally.
Deferiprone Sector: Growth Drivers and Challenges
Growth Drivers
- Increase in iron overload diseases: The occurrence of this particular condition has increased due to which the deferiprone market has gained popularity worldwide. As stated in the January 2024 NLM article, approximately 16 million people in America are severely affected by iron overload disorder, either acquired or inherited. Additionally, 1 in every 200 white patients in the U.S. is positive with this health condition, and 10% to 14% can be categorized as genetic mutation carriers. Therefore, this denotes an upsurge in the demand for deferiprone with an aim to combat the condition, which is readily driving the market growth.
- Innovation in deferiprone preparations: The aspect of research and developmental activities is yet another factor responsible for the upliftment of the deferiprone market internationally. The constant exertions in revolution are pitched towards increasing the efficiency of the drug while diminishing side effects, with the decisive objective of refining patient loyalty. According to the 2020 Research America Organization report, health and medical R&D investment accounts for almost 5.9% of the total spending in the U.S. Hence, with such contributions, the industry is focused on advancements that create a prolific opportunity for the market to expand.
Challenges
- Issues in patient compliance: The deferiprone market is expected to face hindrance owing to patients encountering adverse as well as side effects after the treatment procedure. In the case of extended intake of deferiprone, consent should be taken from patients to maintain basic compliance throughout the procedure. The implementation of regulations is essential for great caution that is strictly imposed by administrative bodies, especially during the drug delivery procedure.
- Strict regulatory policies: The deferiprone market often faces backlash owing to the presence of stringent policies and strategies that are initiated by governments and administrations. The ongoing investments pertaining to time and capital result in delayed formulations in the market. In addition, the conduct of clinical trials based on policies is quite time-consuming, due to which healthcare providers are unable to provide care, and patients are unable to receive the required treatment to combat their health conditions.
Deferiprone Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.8% |
|
Base Year Market Size (2024) |
USD 40 million |
|
Forecast Year Market Size (2037) |
USD 62.5 million |
|
Regional Scope |
|
Deferiprone Segmentation
Type (Tablet, Oral Solution, Capsule)
Based on type, the tablet segment is expected to hold over 83.5% deferiprone market share by the end of 2037. Factors such as easy portability, simple administration, and widespread acceptance are responsible for the expansion of the segment. As per a review-based study conducted by the Clinical Epidemiology and Global Health in April 2022, there is the presence of the Weekly Iron and Folic Acid Supplementation (WIFS) Program that is available for teenagers owing to the rising incidence of anaemia. This program focuses on 52 weeks of iron-folic acid (IFA) tablet delivery under regulation, thus amplifying the segment’s development.
Indication (Transfusional Iron Overload, NTDT CAused Overload)
By the end of 2037, transfusional iron overload segment is set to account for more than 65.5% deferiprone market share. The segment’s growth is fueled by the increase in individuals undergoing rapid transfusions for blood support. According to the February 2024 NLM article, blood transfusion comprises approximately 200 to 250 mg of iron, and patients with more than 10 to 20 units of blood transfusions are more likely to develop iron overload. Therefore, the tight regulation of iron recycling and absorption is necessary to combat this situation, which effectively drives the market growth.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Indication |
|
|
Therapeutic Use |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportDeferiprone Industry - Regional Synopsis
North America Market Analysis
North America deferiprone market is projected to account for revenue share of around 43.5% by 2037. The growth is attributed to the stringent administrative policies for the maintenance of efficacy and safety, an effective connection between patients and healthcare professionals, and the presence of advanced therapeutic and treatment solutions. Furthermore, the overall population in the region is extremely aware of iron deficiency disorders as well as available medical options to overcome them. There has been the launch of educational programs for health interns and full-time providers, thereby all catering to the market upliftment.
The presence of the U.S. FDA is the ultimate growth factor for bolstering the deferiprone market in the U.S. For instance, in December 2023, the regulatory body accepted the use of two milestone treatments- Casgevy and Lyfgenia. Both of these represent the first cell-based gene therapies for the treatment of sickle cell disease in patients more than 12 years of age. In addition, Casgevy is the first treatment approved by the body to implement a particular type of innovative genome editing technology that signals a progressive advancement in the field of gene therapy, thereby uplifting the market in the country.
The deferiprone market in Canada is projected to expand owing to the occurrence of iron deficiency conditions. In this regard, a clinical study was conducted by The Journal of Nutrition in May 2023 to determine the prevalence of these conditions in the country. Out of the total population, the incidence of iron deficiency is 7%, 6.1% of anaemia, and 2.0% of iron deficiency anemia. Therefore, this determines the increasing need for deferiprone to rapidly combat these conditions among the regional population. Also, the inclusion of the government and administrative organizations drives the market development in the country.
APAC Market Statistics
The Asia Pacific is poised to account for a significant share in the deferiprone market by the end of the forecast period. The medicated product has gained economic benefit owing to its acceptance as an alternative to deferoxamine in overcoming iron overload complications. It is readily available in many countries such as India and China owing to the presence of manufacturers and suppliers. Also, the presence of regulatory bodies plays a vital role in approving the product that are launched by organizations from other regions, thus enhancing the market evolution and demand.
The deferiprone market in India is significantly experiencing growth owing to the presence of a huge number of suppliers. For instance, Taj Pharmaceuticals is one of the manufacturers of the deferiprone capsule in the country. As per its 2025 article, the organization commercializes the product in 250 mg and 500 mg in the form of oral administration with a package facility of 30, 90, and 100. In addition, the organization highly focuses on high standards and high quality, and ensures strict measures for every batch of medicines in a harmonious way. Therefore, the availability of deferiprone through manufacturers is a huge opportunity for the market to grow in the country.
The deferiprone market in China is gaining extreme exposure owing to the presence and effective functioning of regional administrative bodies in approving products launched by international organizations. For instance, in November 2022, Fresenius Kabi and CSL Vifor declared that China’s National Medical Products Administration (NMPA) has permitted Ferinject, which is a preparation for intravenous iron therapy for the ailment of iron deficit. It is suitable for adult patients in the country for whom oral iron preparations are ineffective, thus enhancing the market demand.
Companies Dominating the Deferiprone Landscape
- Apotex Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cipla Limited
- VHB Life Sciences Limited
- Taro Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Novartis International AG
- Chiesi Farmaceutici S.p.A.
- Zydus Cadila
- Terumo Blood and Cell Technologies
- Vertex Pharmaceuticals
- Forma Therapeutics, Holdings Inc.
- Novo Nordisk
Organizations are making effective contributions to escalate pharmaceutical excellence which is suitable for the expansion of the deferiprone market globally. The aspect of collaboration between regulatory bodies and organizations is the most suitable factor for the upliftment of the market internationally. For instance, in February 2025, Terumo Blood and Cell Technologies declared its partnership with the National Alliance of Sickle Cell Centers (NASCC). The organization aims to improve the lives of people with sickle cell disease by addressing barriers in access to blood transfusion therapy and assisting in educating healthcare providers about transfusion therapy utilization to improve patient outcomes.
Here's the list of some key players:
In the News
- In January 2025, Vertex Pharmaceuticals notified its reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY.
- In September 2022, Forma Therapeutics, Holdings Inc. and Novo Nordisk entered into a definitive agreement under which Nordisk acquired Forma Therapeutics for USD 20 per share in cash, which represents a total equity value of USD 1.1bn to transform the lives of patients with sickle cell disease (SCD) and rare blood disorders.
Author Credits: Radhika Pawar
- Report ID: 7559
- Published Date: Apr 25, 2025
- Report Format: PDF, PPT
